Joycelin Canavan

POSEIDON IPD meta-analysis #ASCOGU26 • Adding ADT to salvage RT → No significant OS benefit (HR 0.87) • PSA ≤0.5? RT alone often enough • PSA >1.6? Consider long-term ADT Risk-adapted > Routine ADT #MVOnco #ProstateCancer #GUOnc

Stereotactic radiation outperforms hippocampal-avoidance whole brain radiation for 5–20 brain metastases. It better reduces symptoms and protects daily function. @JAMA_current @BrighamWomens @AyalAizer @OncoAlert

Yep. Plenty of reasons one might choose surgery over #radiotherapy, but the “can’t have surgery later” fear makes even less sense as an increasing # of effective alternatives emerge. “Losing” an option you don’t need is not a loss. This isn’t a knock on surgery, it’s a win for #prostatecancer patients.

Interpreting liver mets on MRI can be challenging, in part b/c imaging features (hypo vs hypervascularity) vary by primary tumor site. I adapted this slide from Dr. Jim Apisarnthanarax presentation at ASTRO. Important for diagnosing & if treating w MR-guided RT.

How to decide PMRT in pT3NoMo Magee Equations score Clinicopathological factors (tumor size, grade, ER, PR, HER2, and Ki67) If score <18 no benefit with PMRT Safely Omit PMRT If score >18 [ no PMRT group had a higher LRR rate compared to the PMRT group ](11% vs. 2%; P =.01)

#ESTRO25 Press release:  Two-Week Radiotherapy Proven as Safe and Effective as Eight-Week Course for #ProstateCancer, After 10-Year Follow-Up in Phase III Trial. 👉 bit.ly/3RNnw3B

Excellent review - Management of hepatocellular cancer ascopubs.org/doi/10.1200/OP… @JCOOP_ASCO @OncoAlert @RyanNipp @ASCO

Phase II study @TheLancetOncol for unresectable stage III NSCLC: SBRT to primary then chemoradiation to nodes then durvalumab. 1y PFS 63% does not meet primary endpoint but favorable efficacy & safety vs historic standards. Phase III NRG LU008 underway. thelancet.com/journals/lanon…

☢️💊💉Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure! ✅ 3-year freedom from cystectomy: 88% ✅ 3-year OS: 69% ✅Distant metastasis at 3 years: 12% An alternative to radical cystectomy, but safety monitoring is key. #BladderCancer #Oncology #PrecisionMedicine @OncoAlert @JCO_ASCO doi.org/10.1200/JCO.23…

‼️ EUROPA interim Ph3 RCT 70+ y/o low risk breast cancer -> BCS -> adjuvant endocrine only vs adjuvant APBI only APBI has better HRQoL than endocrine tx, adj mean difference 6.39 (0.14-12.65) 0 IBTR, LRR, or DM events!! 🤩 #SABCS24

🔥@NRGonc dose escalated #radonc contouring atlas for inoperable #pancreaticcancer in press!🔥 ➡️Step-by-step recs for anatomically derived CTV ➡️Dose escalation strategies suggested ➡️Will be reference for upcoming ph3 NRG GI011 trial that requires CTV redjournal.org/article/S0360-…

Review on how to use of radiation for treatment of arthritis, was great to work on this with @SprakerMDPhD @drbeckta @jamesbyu Dr. Brower, and Dr. Grew now available in PRO: sciencedirect.com/science/articl…

On happiness…

Burnout & moral injury in medicine have affected so many health care workers. As a mid-career physician, here’s what I’ve learned to combat it - I hope others find it to be helpful. In Search of Joy and Meaning in Modern Medicine @JCOOP_ASCO ascopubs.org/doi/pdf/10.120…

Patients affected by para-aortic disease might have a PFS comparable to pelvic ones; LC is high in both cohorts. Our results also support the use of #SBRT for para-aortic #oligometastases

A new #RedJournal special issue has published, PENTEC: Pediatric Normal Tissue Effects in the Clinic. This special issue represents years of work researching and writing critical reviews about the treatment of childhood cancers. ow.ly/OQoa50S7IFN

PRESS RELEASE: NRG Oncology Abstract Considered “Best of ASCO” for 2024 Shows Difference in Outcomes for Node-Negative Versus Node-Positive Pancreatic Cancer Patients when Adding Chemoradiation to Systemic Therapy - Read the release: ow.ly/6K0o50S8Nwf

Check out our new #Yonsei paper on 5fx ablative RT for primary breast tumors.🇰🇷🇨🇦 Excited for BC Cancer's upcoming SABR-PRIMeR trial led by Andrew Bang.📢More attention should be paid to these breast SABR (-ish) approaches in stage IV BC. ejbc.kr/DOIx.php?id=10…

New in @JCO_ASCO: @ASCO @CancerCareMASCC @isooworld multidisciplinary evidence-based recommendations for prevention and management of #osteoradionecrosis (#ORN) of the jaw secondary to head & neck #radiation therapy in patients with cancer. #hncsm #radonc ascopubs.org/doi/full/10.12…

New in @IJROBP: Phase II trial shows the rate of implant failure in reconstructed pts with #breastCancer treated with IMRT was similar to, but not improved over, conventional, 3D-conformal #radiation. #bcsm serial MRIs may detect early capsular contracture #fig0001" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…